ProCE Banner Activity

Current Treatment Landscape and Promising New Therapies for Patients With Prurigo Nodularis

Clinical Thought

While prurigo nodularis (PN) may be a result of several underlying conditions, it is a distinct clinical entity that may persist despite removal of the underlying cause. Several promising agents in phase III trials may provide significant long-term relief.

Released: September 16, 2022

Share

Faculty

Benjamin Ungar

Benjamin Ungar, MD

Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Sanofi and Regeneron Pharmaceuticals

Faculty Disclosure

Primary Author

Benjamin Ungar, MD

Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Benjamin Ungar, MD: consultant/advisor/speaker: Arcutis; researcher: Incyte, Pfizer, Rapt Therapeutics.